Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 21Active not recruiting 6Terminated 5Recruiting 5Withdrawn 1Unknown 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 59Squamous Cell Carcinoma of Head and Neck 38Nasopharyngeal Carcinoma 27Lung Neoplasms 26Biliary Tract Neoplasms 24Uterine Cervical Neoplasms 23Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 19Cholangiocarcinoma 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 14Ovarian Neoplasms 14Neoplasms 14Neoplasm Metastasis 13Esophageal Neoplasms 13Colorectal Neoplasms 12Carcinoma 12Stomach Neoplasms 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Carcinoma, Transitional Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Recurrence 6Pancreatic Neoplasms 6Nasopharyngeal Neoplasms 5Gallbladder Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5

Interventions

Gemcitabine 7Oxaliplatin 6Cisplatin 5durvalumab 3130-nm albumin-bound paclitaxel 3pembrolizumab 2Leucovorin 2Drug Therapy 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1sintilimab 1pertuzumab 1anlotinib 1Trastuzumab 1Taxes 1Standard of Care 1Platinum 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × Cisplatin × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT05285358 2026-03-13

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

City of Hope Medical Center

Phase 1 Recruiting
12 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT07025174 2025-06-17

SAIB

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06214572 2025-04-11

RUGB

Tata Memorial Centre

Phase 2/3 Recruiting
249 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡